Identity
Novartis Farmaceutica, S.A.
| Year | Amount | Distribution |
|---|---|---|
| 2026* | €96.7M | |
| 2025 | €201.0M | |
| 2024 | €126.4M | |
| + regional platforms | ||
| 2023 | €85.1M | |
| 2022 | €29.6M | |
| 2021 | €73.7M | |
| 2020 | €34.3M | |
| 2019 | €63.5M | |
| 2018 | €6.5M | |
| 2017 | €0.3M | |
| 2016 | €<0.1M | |
In figures
Volume
Between 2016 and 2026 it won 1,286 contracts worth €717M on its own, with 51 buyers. Its 9 joint-venture (UTE) contracts are shown separately.
Price
It has fewer than 3 comparable awards, too few to compute its median discount.
Competition
Since 2024, <1% of its comparable value was won with a discount and against other bidders. It was the only bidder in 96% of its contracts (2016–2026).
Renewals
94 contracts (€50.5M) come up for tender again in the next 24 months.
A UTE is a temporary joint venture: the contract is awarded to the UTE and each partner's share is not published. That is why these contracts are not added to Novartis Farmaceutica, S.A.'s total, and under «Show UTEs» the amounts are the full value of each contract (100%), not Novartis Farmaceutica, S.A.'s share.
Data up to 31 October 2026 · updated on 12 November 2026 · Source: official data, national and regional coverage
| UTE partners | Contracts | Total value (100 %) |
|---|
Its discounts
The discount at which it wins contested contracts, year by year.
Only 1 contested award can be compared — not enough to read how it prices. Of its 1,286 contracts, 848 are call-offs under framework agreements and 226 were awarded without competition (negotiated without publicity or direct award).
Framework call-offs 848 · Single bidder 29 · Non-competitive procedure 226 · No comparable budget 182 · Contested, comparable 1
Where it wins, and at what discount
In the report · these discounts, one by one
Each dot on the chart is an award. The report lists them all and groups them by buyer and by sector, next to the discounts of other companies with the same buyers.
Full list: date, buyer, amount, budget, discount, bidders and a link to the official publication.
How it wins
Whether it wins with or without competition.
93% of the comparable value since 2024 (€871k of €936k) was won at the tender price and without other bidders. Only €64.0k (7%) was awarded with a discount and without other bidders.
Comparable: 14 awards with a published budget and bidder count (€936k of €424M awarded since 2024). Percentages of value; the figure next to «bidders» is the number of awards. Source: official data, national and regional coverage.
Between 2016 and 2026, 71.8% of the value was awarded through negotiated without publicity procedure (51.2% of contracts); followed by Based on a framework agreement (14.1%) and Other (7.6%).
Upcoming tenders and main buyers
When its contracts come back and who it sells to.
In the next 24 months 94 of its contracts come up for tender again, worth €50.5M.
| Expected end | Buyer | Value |
|---|---|---|
| 2026 | Gerencia de Atención Sanitaria del Instituto Nacional de Gestión Sanitaria en Ceuta | €229k |
| 2026 | Hospital Universitario de Fuenlabrada | €194k |
| 2026 | Hospital Universitario Fundación Alcorcón | €183k |
| 2026 | Gerencia de Servicio Sanitarios de Fuerteventura | €7.08k |
| 2026 | Gerencia de Servicio Sanitarios de Fuerteventura | €1.42k |
and 89 more in the next 24 months · the report includes them all
Expected end year from the published duration (no extensions). The report includes the month and the discount it won each one at.
| Buyer | Contracts | Value, € | Period |
|---|---|---|---|
| Gerencia de Servicio Sanitarios de Fuerteventura | 800 | 195 M | 2018–2026 |
| Servicio Andaluz de Salud | 51 | 105 M | 2024–2026 |
| OSAKIDETZA - Servicio Vasco de Salud -Director General | 25 | 50 M | 2024–2026 |
| Gerencia Regional de Salud de Castilla y León | 13 | 48 M | 2018–2026 |
| Dirección General de Planificación Económica | 37 | 45 M | 2018–2026 |
and 46 more buyers
Between 2016 and 2026, 100.0% of the value it won on its own is in Medical & pharmaceuticals (CPV 33, 1,262 contracts).
Recent awards
The evidence behind every insight in the report.
| Date | Contract | Buyer | Bidders | Value |
|---|---|---|---|---|
| 11/09/2026 | Lutecio (177LU) 1000 MBQ/ml solución inyectable y para perfusión (Vipivotida Tetraxetan). "Emergenc… | Servicio Cántabro de Salud | 1 | €83.4k |
| 03/09/2026 | Lutecio (177LU) 1000 MBQ/ml solución inyectable y para perfusión (Vipivotida Tetraxetan). "Emergenc… | Servicio Cántabro de Salud | 1 | €83.4k |
| 29/07/2026 | Lutecio (177LU) 1000 MBQ/ml solución inyectable y para perfusión (Vipivotida Tetraxetan). "Emergenc… | Servicio Cántabro de Salud | 1 | €83.4k |
| 03/07/2026 | Suministro de medicamentos de uso humano tipo II (Exclusivos), con destino al Servicio de Farmacia … | Dirección Gerente del Hospital Universitario Nuestra Señora de Candelaria | 1 | €80.4k |
| 08/06/2026 | cpca 1º cbam novartis farmaceutica, s.a. exp. 578/2025 suministro medicamento exclusivos cca: +6.i+… | Servicio Andaluz de Salud | 1 | €913k |